INTRODUCTION
Myeloid-suppressor cells include immature types of macrophages, granulocytes, dendritic cells (DCs) and myeloid-progenitor cells. They contribute to a negative regulation of both adaptive and innate immune responses during cancer and other diseases. In mice, such cells are characterized by the expression of CD11b and the myeloid-cell lineage differentiation antigen Gr-1. Two subsets have been distinguished, the granulocytic myeloid cells that are CD11b þ Gr-1 high and the monocytic myeloid cells that are CD11b . Suppressive myeloid cells utilize several inhibitory mechanisms that vary among the different subpopulations. The most frequently reported mechanisms are the production of Arginase-1, reactive oxygen species, nitric oxide and the induction of T regulatory cells. 1 The granulocytic myeloid cells produce reactive oxygen species while the monocytic myeloid cells produce nitric oxide. 2 Important factors that promote suppressive myeloid cells include interleukin (IL)-10, transforming growth factor (TGF)-b, IL-6, vascular endothelial growth factor, granulocyte/macrophage colony-stimulating factors and prostaglandins (for example, prostaglandin E 2 (PGE 2 )). 3 The tumor and its stroma produce large quantities of such molecules. Myeloid cells expanded in cancer patients participate to block any attempt of the immune system to attack the tumor. Other factors, such as CD40 ligand (CD40L), may instead stimulate myeloid DCs to become potent immune stimulators and initiators of anti-tumor immune reactions. 4 Various immunotherapies, such as T-cell therapy, are investigated in clinical trials to treat cancer. 5, 6 Due to the strong inhibition of T cells by suppressive myeloid cells, the elimination of those in the tumor microenvironment may enhance efficacy of immunotherapy.
CD40L is a member of the tumor necrosis factor family of proteins. It is expressed by a variety of activated cells such as T helper (Th) cells. CD40L is also produced and stored in vesicles of platelets that release soluble CD40L upon their activation. CD40L binds to the CD40 receptor present on immune cells, epithelial and endothelial cells. Upon ligation, the CD40 þ cell is commonly activated to release inflammatory cytokines, upregulate receptors such as major histocompatibility complex molecules and death receptors. CD40L-CD40 ligation on DCs promotes their differentiation into activated mature DCs with enhanced capacity to initiate T-cell responses. 4 In contrast, most CD40 þ tumor cells react with cell cycle arrest or apoptosis upon CD40L ligation. 7 CD40-targeting therapies such as CD40L gene therapy (AdCD40L) have shown promising results in cancer models (mouse), in dog patients and in man (clinical phase I-II trials). [8] [9] [10] [11] [12] We have previously shown that CD40L tilts the immunological responses in the tumor from a suppressive cytokine environment to a Th1 milieu. 13 However, it remains unclear whether CD40L can affect the levels of myeloid cells in the tumor. Hence, in this study, the level and phenotype of myeloid cells after AdCD40L therapy was investigated. The results revealed that CD40L therapy may be an interesting adjuvant to T-cell therapy owing to its capacity to shift the myeloid cell populations and promote infiltration of T cells into the tumor.
MATERIALS AND METHODS

Cell lines and culture
The mouse bladder carcinoma cell line MB49, derived from C57BL/6 mice, was a kind gift from Dr Esuvaranathan (National University Hospital, Singapore, Singapore). The cells were cultured in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum, 1% penicillin/ streptomycin and 0.1% sodium pyruvate. Medium and supplements were purchased from Life Technologies (Paisley, UK).
Production of recombinant adenovirus
Vectors were constructed and produced as has been described previously. 13 Briefly, two replication-deficient, E1/E3-deleted, human adenoviruses type 5 were produced using the AdEasy system. The AdCD40L virus codes for the murine CD40L molecule, and the AdMock is a noncoding control virus. Adenoviruses were produced by four rounds of infection of 911 cells. Purification was done in two steps, first by a discontinuous Cesium Chloride (CsCl) gradient and secondly by removing the CsCl by desalting. Virus titers were determined by a fluorescence forming unit (ffu) assay where 911 cells were plated on collagen-coated 35 mM plates with grids (Sarstedt, Nü mbrecht, Germany) and infected with the purified virus in different dilutions. The cells were cultured for 48 h, and after a washing with phosphate-buffered saline (PBS), fixed in 4% paraformaldehyde. The cells were washed with PBS and then incubated with a mouse monoclonal anti-adenovirus antibody (Merck KGaA, Darmstadt, Germany) for 1 h at room temperature. The cells were washed with PBS and then incubated with a secondary fluorescein isothiocyanate (FITC)-labeled polyclonal rabbit anti-mouse antibody (DakoCytomation, Glostrup, Denmark) for 1 h, light protected, in room temperature. The cells were washed once in PBS, and subsequently green cells were counted by using a microscope with a fluorescence illuminator (Olympus, CK40, Olympus Optical CO GMBH, Hamburg, Germany).
Animal models
Female C57BL/6 mice were obtained from Taconic M&B (Bomholt, Denmark) while CD40 À / À C57BL/6 mice (002928 B6.129P2-CD40otm1-Kik4/J) were obtained from the Jackson Laboratory, Sacramento, CA. . Asterisk (*) demonstrates significant differences with Po0.05 using the log-rank survival test.
incubation with primary antibodies (2 mg ml À 1 , phycoerythrin (PE)-conjugated rat anti-mouse CD11b (Clone M1/70, BD), FITC-conjugated rat anti-mouse Gr-1 (Clone RB6-8C5, BD Biosciences) diluted in blocking solution for 1 h at room temperture. Nuclei were counterstained with 2-mg ml À 1 Hoechst 33342 (Sigma-Aldrich), followed by extensive washing in PBS and mounting with Fluoromount G (Southern Biotech, Birmingham, AL, USA). Microscopic pictures covering one entire tumor section per sample were taken on a Nikon Eclipse E100 microscope equipped with a Nikon DXM 1200 camera (Nikon Instruments Europe, Amstelveen, The Netherlands) using a PlanApochromat 20 Â /0.75 objective (Nikon). Images were analyzed with ImageJ (NIH, Bethesda, MD, USA). To determine the number of CD11b þ Gr-1 þ cells, double-positive area was defined by manual thresholding, and the nuclei within this area and the region of interest (ROI) were counted. The number of cells was expressed in relation to the total ROI.
Myeloid cell sorting
For the myeloid cell cultures, spleens from MB49 tumor-bearing mice were collected, and splenocytes were enriched for Ly6G þ cells with magneticactivated cell sorting beads (Miltenyi Biotec, Gergisch Gladbach, Germany). A purity of 40-50% was achieved.
Splenocyte-MB49 co-culturing
Splenocytes from a naive C57BL/6 mouse were obtained as follows. The spleen was kept in RPMI (Invitrogen, Paisley, UK) and cut into small pieces. Liberase (Roche Diagnostics GmbH, Mannheim, Germany) was added to a final concentration of 0.6 mg ml À 1 . The suspension was incubated for 15 min at 37 1C. EDTA was then added to a final concentration of 10 mM. The splenocytes were passed through a MESH membrane (BD Biosciences), washed and the required amount of cells were used for co-culturing in a 10:1 ratio with MB49 cells that were either untransduced or transduced with 500 MOI AdMock or AdCD40L. The MB49 cells were irradiated at 80 Gy before co-culture. After 72 h, the cells were harvested and analyzed by flow cytometry. Myeloid cells differentiate in response to various stimuli while lymphocytes tend to both differentiate and proliferate. To avoid 'false' changes in myeloid cell populations owing to lymphocyte proliferation, the CD11b þ myeloid cells were gated, and all analyses performed on these cells. See further gating strategy in the 'Flow cytometry' section for description and Supplementary Figure S1 .
Flow cytometry
Cells from the co-cultures and animal experiments were stained with fluorescently labeled antibodies against CD11b (PE, PerCP), Gr-1 (Alexa Fluor 647, PE-Cy7), B220 (FITC, Pacific Blue), CD11c (PE) and CD40 (FITC, allophycocyanin) (clone HM40-3 or 3/23) (Biolegend, San Diego, CA, USA). MB49 cells were stained for expression of CD40L using a PE-labeled monoclonal antibody (clone MR1) also from BioLegend. All cell suspensions were incubated with antibodies diluted in 1% bovine serum albumin in PBS for 30 min in 4 1C, washed twice with 1% bovine serum albumin in PBS and then analyzed immediately by flow cytometry (FACSCanto II, BD Biosciences). Data analysis was performed using FlowJo software (Treestar Inc., Ashland, OR, USA). The following cell populations were investigated:
The myeloid gating strategy was to plot CD11b against CD11c, gate the CD11b cells and then plot these cells against B220 and gate the B220-negative cells. These CD11b þ B220 À cells were plotted against Gr-1 and the two subpopulations of granulocytic and monocytic myeloid cells could be visualized. The M1 and M2 macrophages were determined by taking the F4/80 þ cells from the viable cell population, thereafter the double-positive F4/80 þ CD11b þ cells were gated. These cells were then plotted against CD11c and CD206. The CD11c þ CD206 À cells were determined as M1 macrophages, and the CD206 þ cells were determined as M2 macrophages.
Enzyme-linked immunosorbent assay
Supernatants were collected from transduced (AdCD40L or AdMock) and untransduced MB49 cells after 72 h, freezed and later analyzed by Prostaglandin E2 enzyme-linked immunosorbent assay (Arbor Assays, Ann Arbor, MI, USA) according to the protocols from the manufacturer.
Statistical analyses
P-values o0.05 were considered significant. All statistical analyses were performed using the Graph Pad Prism 4.0/5.0 (Graph Pad Software, San Diego, CA, USA). The different tests used are stated in the figure legends.
RESULTS
CD40L therapy is efficient in experimental bladder cancer
To evaluate the efficacy of local AdCD40L cancer therapy and its effect on myeloid cells as well as on T cells, an adenovirus vector carrying the murine CD40L gene (AdCD40L) was administered to the bladders in a model of orthotopic bladder cancer or intratumoral in subcutaneously growing tumors. The efficacy of AdCD40L therapy to reduce tumor growth and cure mice with established tumors is shown in a subcutaneous ( Figure 1a ) and in two orthotopic bladder models (Figure 1b) where the mice 14 Therefore, we sought to investigate the presence of infiltrating myeloid cells and T-cell activation status in our model. Local AdCD40L therapy reduces myeloid cells in the tumor and increases cytotoxic T cells AdCD40L-treated subcutaneous tumors were mechanically disrupted and analyzed by flow cytometry for infiltrating myeloid cells while orthotopic tumors were investigated by immunohistochemistry. The overall myeloid cell population in subcutaneous tumors was not affected by AdCD40L therapy (Figure 2a) . However, the monocytic CD11b þ Gr-1 int/low cells were decreased (data not shown), whereas the granulocytic cells were increased (Figure 2b) . In the orthotopic model, AdCD40L therapy induced a substantial decrease of myeloid cells as defined by CD11b þ Gr-1 þ staining (Figure 2c ). Correspondingly, in AdCD40L-treated tumors containing a reduced level of myeloid cells, the level of activated CD107a þ CD3 þ T cells was higher than in AdMock-treated tumors (Figure 2d ), although not significant (P ¼ 0.057) owing to one AdMock-treated mouse with an out layer value of 30% positive cells. We further analyzed the number of CD3 þ Th (CD4) or cytotoxic (CD8) T cells in the draining lymph nodes 24 h post first AdCD40L treatment (early) and at day 20 (late). In Figure 3a , it is shown that in the lymph nodes of both AdMock-and AdCD40L-treated animals the CD8 T-cell population is expanded during treatment while the CD4 to CD8 T-cell ratio is thereafter normalized to more CD4 cells than CD8 cells (Figure 3b ). During treatment with any adenoviral vector, the CD4 T cells were significantly reduced (Figure 3c ), whereas the CD8 T cells were instead significantly increased ( Figure 3d ) compared with day 20.
MB49 cells promote survival and expansion of myeloid cells in vitro
To define the mechanism of the CD40L-mediated reduction of myeloid cell populations, we simulated the tumor microenvironment by performing in vitro co-cultures of sorted myeloid cells and tumor cells. The level of CD40-expressing myeloid cells from tumor-bearing mice was determined. CD40 expression was analyzed by flow cytometry on both the CD11b þ Gr-1 high and CD11b þ Gr-1 int/low myeloid cells (Figure 4a , gating strategy in Supplementary Figure S1 ). Approximately, 1% of the CD11b þ Gr-1 high cells and 21% of the CD11b þ Gr-1 int/low cells were CD40 positive. MB49 cells were transduced with AdCD40L, AdMock or left untransduced. After transduction, the AdCD40L-transduced cells were expressing CD40L, whereas the others did not (Figure 4b ). The MB49 cells were then co-cultured with myeloid cells sorted by the Gr-1/Ly6G separation kit. Myeloid cells cultured alone rapidly lost viability, whereas co-culture with MB49 tumor cells promoted their survival (Figure 2c ). CD40L could not inhibit the MB49-induced survival of the myeloid cells. We have previously shown that MB49 cells express TGF-b that promotes expansion of myeloid cells. Another important factor is PGE 2 . Supernatants from MB49 cells pretreated with PBS, AdMock or AdCD40L were harvested and analyzed for PGE 2 . MB49 cells 
CD40L shifts the ratio of granulocytic and monocytic myeloid cells
To further define the myeloid cells before and after CD40L stimulation, splenocytes from wild-type C57BL/6 mice were cocultured with MB49 cells that were either untransduced (MB49), transduced with AdMock (MB49-Mock) or AdCD40L (MB49-CD40L). After 72 h, the cells were harvested and analyzed by flow cytometry. The results revealed that there were more granulocytic CD11b þ Gr-1 high myeloid cells and less monocytic CD11b þ Gr-1 int/low myeloid cells in the AdCD40L group (Figure 5a , Po0.0001), indicating that CD40L may induce a shift in the myeloid cell differentiation route. As CD40 was present on monocytic myeloid cells but almost lacking on the granulocytic cells, the monocytic myeloid cells may be the cells that were affected by CD40L. However, the co-culture may increase CD40 in cells. Hence, the expression of CD40 on both the Gr-1 high and the Gr-1 int/low cells after co-culture was investigated. CD40 expression was increased in both subpopulations when compared with the co-culture with untransduced MB49 cells (Figures 5b and c) . For CD11b þ Gr-1 int/low cells, the increase was higher in the MB49-CD40L group than in the MB49-Mock group (P ¼ 0.0411). To ensure that it was indeed the CD40-CD40L interaction that tilted the myeloid cells toward the granulocytic subtype, we repeated the experiments using splenocytes from both wild-type and CD40
À / À C57BL/6 mice. The CD40 À / À data did not demonstrate a similar shift in the myeloid cell subpopulations, confirming the importance of CD40L stimulation (Figure 5d ).
M1 macrophages are favored in CD40L-stimulated splenocyte cultures As the granulocytic myeloid (Gr-1 high ) cells expressed a rather low level of CD40, whereas the monocytic (Gr-1 int/low ) cells expressed higher levels, we hypothesized that instead of expanding granulocytic myeloid cells, the monocytic myeloid cells may have þ LY6G þ sorted (granulocytic) myeloid cells were co-cultured with MB49 cells þ / À CD40L at a 1:1 ratio, and the viable cells were determined by trypan blue counting. (d) MB49 cells pretreated with AdCD40L, AdMock or PBS were cultured, and the supernatant was analyzed for the presence of PGE 2 by enzyme-linked immunosorbent assay. The experiments were repeated twice with similar results. *Po0.05, ***Po0.001 as calculated using the Mann-Whitney test.
The AdCD40L effect on myeloid cellsbeen differentiated towards another phenotype. Upon differentiation, monocytes commonly become macrophages. Indepth analysis of the myeloid cell populations demonstrated that macrophages were in general decreased in the MB49-CD40L cocultures (Figure 6a) . However, CD40L expression strongly promoted M1 macrophage differentiation (Figure 6b ; P ¼ 0.0043). The percentage of M2 macrophages within the macrophage population remained the same in all co-cultures (data not shown). Hence, the results presented herein support that CD40L tilts the myeloid cell populations as depicted in a schematic figure that combine these findings with our previously published results on the immunostimulatory properties of AdCD40L (Figure 7) . 13 
DISCUSSION
Immunosuppressive cells are a challenge for cancer immunotherapy, and methods to eliminate them are being investigated. AdCD40L gene therapy introduces the CD40L gene into the tumor microenvironment and has the ability to activate a Th1 anti-tumor immune response. 13 In the present paper, we investigated the CD40L-mediated effects on myeloid cell populations in vivo in the tumor milieu and in vitro in cell culture experiments post AdCD40L treatment of MB49 tumor cells.
AdCD40L therapy has shown efficacy in multiple cancer models, 4 for example, in dogs and humans. In this paper, we demonstrated that orthotopic therapy cured most mice that received a low number of tumor cells (2.5 Â 10 5 ), which gives rise to a slow growing tumor. AdCD40L therapy also had an effect on fast growing tumors obtained by instilling a higher dose of tumor cells (1 Â 10 6 ); however, most mice eventually succumbed to tumor progression.
Local tumors in the human urinary bladder are initially small, and we have treated patients with AdCD40L therapy with interesting results. 10 It is ideal to treat local tumors in the urinary bladder before dissemination. However, for disseminated cancer AdCD40L therapy would benefit from being combined with other treatment strategies. As AdCD40L shifts the tumor cytokine milieu from a dominance of IL-10 and TGF-b towards IL-12 and interferon-g, 10,13 the combination of AdCD40L with other immunotherapies such as adoptive T-cell therapy is of interest.
As most tumors attract and expand suppressive myeloid cells that severely hamper T-cell function, we sought to investigate whether AdCD40L gene therapy affects myeloid cells. Indeed, AdCD40L therapy reduced the overall presence of CD11b þ Gr-1 þ myeloid cells in our orthotopic bladder cancer model. In the subcutaneous model, AdCD40L did not reduce the overall level of CD11b þ Gr-1 þ myeloid cells. Nevertheless, there was a shift from the monocytic CD11b þ Gr-1 int/low cells towards the granulocytic CD11b þ Gr-1 high cells. The difference in response may relate to the fact that there is a certain immunological niche in distinct anatomical compartments that can differently affect the accumulation of cells in response to various stimuli. 15 CD40 is expressed on myeloid-suppressor cells. 16 Interestingly, the monocytic subpopulation expressed CD40 in our experiments, while the granulocytic subpopulation expressed it only slightly. This suggests that the monocytic population was more likely to react to CD40L stimuli, resulting in the ratio shift in favor of granulocytic myeloid cells. In order to investigate this phenomenon further, we performed a series of in vitro experiments. Splenocytes containing various myeloid cell populations were co-cultured with MB49 cells pretreated with AdCD40L, AdMock or PBS. Correspondingly to the in vivo results, the granulocytic (Gr-1 high ) and monocytic (Gr-1 int/low) cells shifted in the favor of granulocytic myeloid cells in response to CD40L-expressing MB49 cells. This could not be seen when splenocytes from CD40 À / À mice were used, demonstrating the importance of the CD40/CD40L interaction. Dolcetti et al. 17 showed that monocytic CD11b þ Gr-1 int myeloid cells were more suppressive against CD8 þ T cells compared with granulocytic CD11b þ Gr-1 high cells, and Movahedi et al. 18 reported similar data. Tumor cells promote survival of myeloid-suppressor cells by producing factors, such as PGE 2 and TGF-b. We have previously shown that MB49 cells produce TGF-b. 13, 19 In this study, we demonstrated that MB49 cells produced PGE 2 and that MB49 cells independently of CD40L expression promoted the survival of sorted myeloid cells. Hence, CD40L may have an important role to tilt the myeloid-suppressor cell subpopulations to less suppressive cells rather than interrupting survival signaling from the tumor.
Macrophages have an important role in the tumor microenvironment. Although M1 macrophages participate in the surveillance of tumors, M2 macrophages promote tumor progression, for example, by downregulating adaptive responses. 20 In response to MB49 cells expressing CD40L, F480
þ CD11b þ macrophages were decreased in the splenocyte co-cultures. However, the remaining macrophages had an M1 phenotype. Possibly, M1 macrophages were derived from the monocytic CD11b þ Gr-1 int/low cells that were decreased in the same cultures. Tumors secrete several factors that can promote M2 macrophages, such as TGF-b and IL-10 (reviewed in Bierie and Moses 21 and Mocellin et al. 22 ). We have previously demonstrated that AdCD40L inhibits induction of these two cytokines in AdCD40L-treated MB49 tumors that may explain why M1 macrophages are favored instead of M2 in our cocultures. 13 Umemura et al.23 demonstrated that tumor-infiltrating myeloid-suppressor cells had both macrophage M1 and M2 characteristics. Interestingly, they showed that upon blocking TGFb the myeloid-suppressor cells differentiated into a M1 phenotype. Hence, the decrease of monocytic CD11b þ Gr-1 int/low myeloid cells in our co-cultures may be a result of CD40L-induced differentiation of these cells into M1 macrophages. This hypothesis is strengthened by the fact that monocytic CD11b þ Gr-1 int/low are indeed able to differentiate. 24 We have previously reported that AdCD40L-transduced MB49 cells can induce the differentiation of immature myeloid DCs into mature, IL-12-producing cells, 13 and this further argues for CD40L as a driving force to tilt the myeloid cell populations in favor of those that promote anti-tumor immune reactions.
Interestingly, upon AdCD40L therapy in our orthotopic model, the number of activated tumor-infiltrating T cells was increased when myeloid cells decreased. The number of T cells was also affected at a systemic level as the tumor-draining lymph nodes showed a significant increase of cytotoxic T cells during AdCD40L therapy. The same was seen with the AdMock vector, demonstrating that the combination of both the adenovirus' capacity to activate immune responses and CD40L-mediated signaling may be of importance for a better T-cell response. However, this remains to be investigated. We have previously shown that AdCD40L therapy of subcutaneous tumors induced systemic T-cell responses that specifically killed the MB49 cells in vitro. 13 Hence, AdCD40L therapy may be an interesting adjuvant therapy to adoptive T-cell transfer because of its capacity to shift the myeloid In conclusion, AdCD40L is an interesting therapy for localized cancer but is not capable of curing mice with large, fast growing tumors. Nevertheless, AdCD40L tilts the myeloid-suppressor cells toward a granulocytic subpopulation and promotes M1 macrophage differentiation. Simultaneously, T cells are attracted to the tumor and remain activated. Hence, it may be of relevance to combine AdCD40L adjuvant therapy with adoptive T-cell transfer to achieve sustained T-cell responses.
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